Gracell Biotechnologies Stock Price To Sales
Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
Gracell |
Gracell Biotechnologies Company Price To Sales Analysis
Gracell Biotechnologies' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Gracell Biotechnologies Price To Sales | 732.21 X |
Most of Gracell Biotechnologies' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gracell Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Gracell Biotechnologies has a Price To Sales of 732 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Gracell Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.Gracell Biotechnologies is currently under evaluation in price to sales category among its peers.
Gracell Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Shares Owned By Insiders | 16.39 % | |||
| Shares Owned By Institutions | 63.11 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| Gross Profit | 366 K | |||
| EBITDA | (509.64 M) | |||
| Net Income | (496.98 M) | |||
| Cash And Equivalents | 1.71 B | |||
| Cash Per Share | 25.28 X | |||
| Total Debt | 182.98 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 8.01 X | |||
| Book Value Per Share | 16.90 X | |||
| Cash Flow From Operations | (482.65 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (0.97) X | |||
| Target Price | 10.58 | |||
| Number Of Employees | 314 | |||
| Beta | -0.34 | |||
| Market Capitalization | 989.87 M | |||
| Total Asset | 1.66 B | |||
| Retained Earnings | (1.63 B) | |||
| Working Capital | 1.28 B | |||
| Z Score | 1.78 | |||
| Net Asset | 1.66 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance |